Pnet periférico de región inguinal con respuesta favorable a QT- Talidomida Neoadyuvante: Peripheral pnet of the inguinal region with favorable response to QT-Thalidomide Neoadjuvant     |     腹股沟区域的外周 PNET 对新辅助化疗-沙利度胺的良好反应

Rolig  Aliaga-Chávez; Litze Torvisco-Inca

doi:10.25176/RFMH.v24i4.6611

Authors

Rolig Aliaga-Chávez Hospital Nacional Arzobispo Loayza. Lima, Perú
Litze Torvisco-Inca Universidad Ricardo Palma. Lima. Perú

DOI:

https://doi.org/10.25176/RFMH.v24i4.6611

Keywords:

Groin, rimitive peripheral neuroectodermal tumor, induction chemotherapy, thalidomide

Abstract

Introduction: Primitive neuroectodermal tumours are a family of neoplasms that derive from the neural crest. They are classified into 3 groups: 1) central PNET, 2) Neuroblastoma and 3) peripheral PNET in peripheral nerves. The aim is to describe the characteristics of the case of a 32-year-old female patient who presented with an inguinal tumour with immunohistochemical profile for peripheral primitive neuroectodermal tumour. Case presentation: 32 year old female patient who presented with a tumour in the inguinal region, the biopsy indicated: small nuclei, hyperchromatic and monomorphous cell neoplasm, the immunohistochemical profile was: synaptophysin positive, neurofilament positive, SOX-11 positive and Ki-67: 70%. Conclusions: pPNTEs can occur in any extracerebral location, should be suspected in patients with round cell neoplasm, small blue. And request immunohistochemical markers: CD45, CD99, FLI-1, neurofilament, synaptophysin, chromogranin, SOX 11, myogenic markers and Ki 67.

Keywords: Groin, Neuroectodermal Tumors, Primitive, Peripheral (source: MeSH - NLM)

Downloads

Download data is not yet available.

Author Biographies

Rolig Aliaga-Chávez , Hospital Nacional Arzobispo Loayza. Lima, Perú

Medical Oncology Service

Medical oncologist

Litze Torvisco-Inca, Universidad Ricardo Palma. Lima. Perú

Faculty of Human Medicine

Sixth year Human Medicine student.

References

Ropper AH, Samuels MA, Klein JP, Prasad S. Neoplasias intracraneales y trastornos paraneoplásicos. En: Adams y Victor Principios de Neurología, 12e [Internet]. New York, NY: McGraw-Hill Education; 2023 [citado 17 de marzo de 2024]. Disponible en: accessmedicina.mhmedical.com/content.aspx?aid=1206367491

Sánchez Acedo C, Muñoz Guerra MF, Naval Gías L, Martos PL, Adrados M. Tumores neuroectodérmicos primitivos periféricos de localización en el área orocervical: presentación de dos casos clínicos. Rev Esp Cir Oral Maxilofac. marzo de 2010;32(1):25-30.

Coffin CM, Dehner LP. Peripheral neurogenic tumors of the soft tissues in children and adolescents: a clinicopathologic study of 139 cases. Pediatr Pathol. 1989;9(4):387-407.

Ghosh A, Saha S, Pal S, Saha PV, Chattopadhyay S. Peripheral primitive neuroectodermal tumor of head-neck region: our experience. Indian J Otolaryngol Head Neck Surg Off Publ Assoc Otolaryngol India. septiembre de 2009;61(3):235-9.

Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 1 de abril de 1991;67(7):1886-93.

Fletcher CDM. Diagnostic Histopathology of Tumors: 2-Volume Set with CD-ROMs. Elsevier Health Sciences; 2007. 1931 p.

Doyle LA. Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer. 2014;120(12):1763-74.

Gao L, Zhu Y, Shi X, Gao Z, Chen X. Peripheral primitive neuroectodermal tumors: A retrospective analysis of 89 cases and literature review. Oncol Lett. diciembre de 2019;18(6):6885-90.

Schmidt D, Herrmann C, Jürgens H, Harms D. Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing’s sarcoma. A report from the Kiel Pediatric Tumor Registry. Cancer. 15 de noviembre de 1991;68(10):2251-9.

Kim KJ, Jang BW, Lee SK, Kim BK, Nam SL. A case of peripheral primitive neuroectodermal tumor of the ovary. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2004;14(2):370-2.

Paz-Gómez FJ. Tumor de células pequeñas redondas y azules: abordaje diagnóstico. 2004;11.

Zimmermann T, Blütters-Sawatzki R, Flechsenhar K, Padberg WM. Peripheral Primitive Neuroectodermal Tumor: Challenge for Multimodal Treatment. World J Surg. 2001;25(11):1367-72.

Lake DF, Briggs AD. Inmunofarmacología. En: Vanderah TW, editor. Katzung Farmacología básica y clínica, 16e [Internet]. New York, NY: McGraw Hill Education; 2024 [citado 11 de septiembre de 2024]. Disponible en: accessmedicina.mhmedical.com/content.aspx?aid=1209515145

Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol. diciembre de 2001;28(6):602-6.

Majumder S, Sreedhara SRC, Banerjee S, Chatterjee S. TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide. Curr Top Med Chem. 2012;12(13):1456-67.

Li Q, Liu Y, Yu Y. Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide. Medicine (Baltimore). 22 de diciembre de 2017;96(51):e9272.

Pramanik R, Agarwala S, Gupta YK, Thulkar S, Vishnubhatla S, Batra A, et al. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial. JAMA Oncol. 1 de septiembre de 2017;3(9):1222-7.